<DOC>
	<DOCNO>NCT01243151</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability repeat dos PF-04950615 ( RN316 ) study volunteer hypercholesterolemia . PF-04950615 investigational drug currently study lipid lower agent .</brief_summary>
	<brief_title>Safety And Tolerability Of Multiple Doses Of PF-04950615 ( RN316 ) In Subjects With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>LDLC must great equal 130 mg/dl BMI must 18.5 40 kg/m2 Japanese volunteer must 4 Japanese grand parent born Japan History cardiovascular cerebrovascular event past year . Poorly control type 1 type 2 diabetes mellitus Subjects take lipid lower therapy within last 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>LDL</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Japanese Volunteers</keyword>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>